VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Boyer, 2009, . A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration., Ophthalmology, 116, 1731, 10.1016/j.ophtha.2009.05.024

Brown, 2006, . Ranibizumab versus verteporfin for neovascular age-related macular degeneration., N Engl J Med, 355, 1432, 10.1056/NEJMoa062655

Fung, 2007, . An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration., Am J Ophthalmol, 143, 566, 10.1016/j.ajo.2007.01.028

Holz, 2011, . Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study., Ophthalmology, 118, 663, 10.1016/j.ophtha.2010.12.019

Lally, 2012, Preferred therapies for neovascular age-related macular degeneration., Curr Opin Ophthalmol, 23, 182, 10.1097/ICU.0b013e328352411c

Lim, 2012, . Age-related macular degeneration., Lancet, 379, 1728, 10.1016/S0140-6736(12)60282-7

Brown, 2011, . Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration., Ophthalmology, 118, 1089, 10.1016/j.ophtha.2011.02.039

Mitchell, 2010, . Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials., Br J Ophthalmol, 94, 2, 10.1136/bjo.2009.159160

Patel, 2011, Review of ranibizumab trials for neovascular age-related macular degeneration., Semin Ophthalmol, 26, 372, 10.3109/08820538.2011.570845

Rosenfeld, 2006, . Ranibizumab for neovascular age-related macular degeneration., N Engl J Med, 355, 1419, 10.1056/NEJMoa054481

Singer, 2012, . HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration., Ophthalmology, 119, 1175, 10.1016/j.ophtha.2011.12.016

Stewart, 2012, . Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)., Retina, 32, 434, 10.1097/IAE.0B013E31822C290F

Fung, 2012, . Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistentrecurrent macular fluid 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)., Eye (Lond), 26, 1181, 10.1038/eye.2012.174

Papadopoulos, 2012, . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab., Angiogenesis, 15, 171, 10.1007/s10456-011-9249-6

Browning, 2012, Aflibercept for age-related macular degeneration: a game-changer or quiet addition Am J O, phthalmol, 154, 222

Stewart, 2008, Predicted biological activity of intravitreal VEGF Trap., Br J Ophthalmol, 92, 667, 10.1136/bjo.2007.134874

Heier, 2012, . Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration., Ophthalmology, 119, 2537, 10.1016/j.ophtha.2012.09.006